Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03326674
Title Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC (CONTESSA)
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements No
Sponsors Odonate Therapeutics, Inc.
Indications

Her2-receptor negative breast cancer

Therapies

Capecitabine

Capecitabine + Tesetaxel

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT


No variant requirements are available.